menu search

Nuvalent to present new preclinical data on ros1-selective inhibitor nvl-520 and alk-selective inhibitor nvl-655 at aacr annual meeting 2022

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating...

March 8, 2022, 5:38 pm

On the front lines of investor recession concerns

The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...

January 26, 2022, 1:54 pm

On the front lines of investor recession concerns

The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...

January 26, 2022, 1:54 pm

On the front lines of investor recession concerns

The Fed is set to conclude its two-day meeting on its policies to address the current inflationary rate and other economic pressures seen recently. In...

January 26, 2022, 1:54 pm

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am


Search within

Pages Search Results: